Shots: The approval is based on P-III KATHERINE study assessing Kadcyla (100/160mg, IV) adjuvant therapy in 1486 patients with HER2+ early BC who did not have pathologic complete response following […]readmore
Shots: The approval is based on P-III KATHERINE study assessing Kadcyla vs Herceptin as adjuvant therapy in people with HER2+ eBC with pathological residual invasive disease in the breast and/or […]readmore
Shots: The CHMP’s recommendation is based on P-III KATHERINE study assessing Kadcyla vs Herceptin as an adjuvant therapy in patients with HER2+ early breast cancer with the residual invasive disease […]readmore
Shots: The application is based on P-III KATHERINE study assessing Kadcyla as adjuvant therapy vs Herceptin in ~ 1,500 patients with HER2+ early breast cancer who had invasive residual disease […]readmore
Shots: The approval is based on P-III KATHERINE study results assessing Kadcyla versus Herceptin in patients with HER2+ early breast cancer (eBC) with the residual invasive disease after neoadjuvant treatment […]readmore
Shots: Immunogen to receive $65M as total deal value and OMERS to get royalties on sales of Kadcyla In 2015, Immunogen & IRH collaborated for Kadcyla’s royalty for $200M, where […]readmore
Shots: The P-III KATHERINE study assessed Kadcyla vs Herceptin (trastuzumab) as an adjuvant therapy for patients with HER2-positive eBC for three years P-III KATHERINE study results: risk of disease recurrence […]readmore
Copyright © 2020 Digiqole. All Right Reserved.